

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	08582/014002
	Serial No.	10/505,375
	Applicant	Fong et al.
	Filing Date	May 10, 2005
	Group	1632
	IDS Filed	October 9, 2009

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Bennett et al., "Interleukin 12 Secretion Enhances Antitumor Efficacy of Oncolytic Herpes Simplex Viral Therapy for Colorectal Cancer," Ann. Surg. 233:819-826, 2001.
	Jarnagin et al., "Neoadjuvant Interleukin-12 Immunogene Therapy Protects Against Cancer Recurrence After Liver Resection in an Animal Model," Ann. Surg. 231:762-771, 2000.
	Markert et al., "Conditionally Replicating Herpes Simplex Virus Mutant, G207 for the Treatment of Malignant Glioma: Results of a Phase I Trial," Gene Ther. 7:867-874, 2000.
	Walker et al., "Local and Systemic Therapy of Human Prostate Adenocarcinoma with the Conditionally Replicating Herpes Simplex Virus Vector G207," Hum. Gene Ther. 10:2237-2243, 1999.
	Notice of Reasons for Rejection (Translation) and pending claims from Japanese Patent Application No. 2003-572444, dispatched September 2, 2009.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	